Section Arrow
Quote
NTLA.NASDAQ
- Intellia Therapeutics
Quotes are at least 15-min delayed:2025/05/30 09:20 EDT
Last
 --
-- (--)
Day High 
-- 
Prev. Close
7.45 
1-M High
9.785 
Volume 
-- 
Bid
7.43
Ask
7.45
Day Low
-- 
Open
-- 
1-M Low
6.9 
Market Cap 
771.70M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 8.96 
20-SMA 8.56 
50-SMA 8.1 
52-W High 28.18 
52-W Low 5.9 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-5.23/-4.31
Enterprise Value
961.65M
Balance Sheet
Book Value Per Share
7.53
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
57.88M
Operating Revenue Per Share
0.51
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ZYMEZymeworks----0.000%-- 
ZVSAZyVersa Therapeutics----0.000%0PE
ZVRAZevra Therapeutics----0.000%-- 
ZURAZura Bio Limited----0.000%5.54PE
ZNTLZentalis Pharmaceuticals----0.000%-- 
Quotes are at least 15-min delayed：2025/05/30 09:20 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.